[EXCLUSIVE] Lobbying Disclosures in the US: How Big Pharma Fought the TRIPS Waiver & is Pushing for Strong Intellectual Property Protection in the Pandemic Agreement
Newsletter Edition #234 [The Files In-Depth]
![[EXCLUSIVE] Lobbying Disclosures in the US: How Big Pharma Fought the TRIPS Waiver & is Pushing for Strong Intellectual Property Protection in the Pandemic Agreement](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w1280/format/webp/substack-post-media-s3-amazonaws-com/public/images/591fd241-c258-4140-ae5f-8cf6837e92b8_5472x3648.jpg)
From our partners
Striking a Balance: Standardization and Flexibility in Pandemic Contracts
Newsletter Edition #158 [Treaty Talks] Subscribe Now! Readers, Making decisions based on incomplete information is a quotidian reality for policymakers. But it is totally unwholesome to those tasked with writing
/
